Posted by Michael Wonder on 06 Jun 2020
AiCuris was granted breakthrough therapy designation by U.S. FDA for pritelivir for the treatment of HSV infections in immunocompromised patients
5 June 2020 - AiCuris is currently preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients whose herpes simplex virus infections have become resistant to acyclovir as a basis for new drug application.
AiCuris today announced that the Company has been granted breakthrough therapy designation by the U.S. FDA for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised adults.
